AC Immune (NASDAQ:ACIU) Receives "Buy" Rating from BTIG Research

Key Points

• BTIG Research has reissued a "buy" rating for AC Immune (NASDAQ:ACIU), with a price target of $8.00, indicating a potential upside of 250.88% from the current stock price.
• The company recently reported a quarterly earnings miss, posting ($0.25) EPS, below analyst expectations, with revenue of $1.65 million.
• Institutional investors hold 51.36% of AC Immune's stock, with significant changes in stakes from firms like BVF Inc. and Acadian Asset Management.

AC Immune (NASDAQ:ACIU - Get Free Report)'s stock had its "buy" rating reaffirmed by equities researchers at BTIG Research in a report issued on Monday,Benzinga reports. They presently have a $8.00 target price on the stock. BTIG Research's price objective points to a potential upside of 229.22% from the company's current price.

Separately, Wall Street Zen upgraded AC Immune from a "hold" rating to a "buy" rating in a report on Tuesday, May 13th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $10.00.

AC Immune Trading Up 2.1%

ACIU stock traded up $0.05 during mid-day trading on Monday, reaching $2.43. The company's stock had a trading volume of 172,212 shares, compared to its average volume of 122,714. The company has a market cap of $244.00 million, a price-to-earnings ratio of -4.19 and a beta of 1.61. The business's 50 day moving average price is $2.17 and its 200 day moving average price is $1.98. AC Immune has a 12 month low of $1.43 and a 12 month high of $3.98.

AC Immune (NASDAQ:ACIU - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported ($0.25) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.05). The business had revenue of $1.65 million during the quarter, compared to the consensus estimate of $1.98 million. AC Immune had a negative return on equity of 49.35% and a negative net margin of 174.94%. As a group, equities analysts expect that AC Immune will post -0.62 EPS for the current fiscal year.

Institutional Investors Weigh In On AC Immune

Hedge funds and other institutional investors have recently modified their holdings of the company. Northern Trust Corp purchased a new position in shares of AC Immune during the fourth quarter valued at approximately $1,088,000. BVF Inc. IL boosted its position in shares of AC Immune by 1.5% during the first quarter. BVF Inc. IL now owns 19,822,436 shares of the company's stock valued at $37,068,000 after buying an additional 300,000 shares during the last quarter. Acadian Asset Management LLC boosted its position in shares of AC Immune by 87.1% during the first quarter. Acadian Asset Management LLC now owns 371,177 shares of the company's stock valued at $679,000 after buying an additional 172,796 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of AC Immune by 130.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 131,410 shares of the company's stock valued at $355,000 after buying an additional 74,358 shares during the last quarter. Finally, Squarepoint Ops LLC purchased a new position in shares of AC Immune during the fourth quarter valued at approximately $118,000. Institutional investors own 51.36% of the company's stock.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.